NCT03557463 is a NA clinical trial of Dairy protein in Immunodeficiency, sponsored by University of California, Davis.

Who is sponsoring NCT03557463?

NCT03557463 is sponsored by University of California, Davis.

What drugs are being tested in NCT03557463?

Interventions in NCT03557463: Dairy protein.

What condition does NCT03557463 study?

NCT03557463 studies Immunodeficiency.

Is NCT03557463 still recruiting?

NCT03557463 is currently completed. Last updated 11 April 2023.

Last reviewed 2023-04-11 · How we verify

NCT03557463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing a Novel Dairy Protein to Counteract Immunosenescence

Completed NA Last updated 11 April 2023

What this trial tests

NA trial testing Dairy protein in Immunodeficiency in 21 participants. Completed in 30 August 2017.

Timeline

1 August 2016

Primary endpoint
1 August 2017

30 August 2017

Quick facts

Lead sponsor	University of California, Davis
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	21
Start date	1 August 2016
Primary completion	1 August 2017
Estimated completion	30 August 2017

Drugs / interventions tested

Dairy protein

Conditions studied

Immunodeficiency — all drugs for Immunodeficiency →

Sponsor

University of California, Davis

Who can join

60 and older, any sex, with Immunodeficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aging populations experience a decline in adaptive immune system function also known as immunosenesence. Nutritional approaches to stimulate and strengthen the immune system are needed for this growing segment of the population. A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response. Our objective was to examine the immune stimulating effects of dairy protein subjected to ultraviolet radiation (UV-C) radiation treatment process instead of pasteurization. Participants were 21 healthy individuals over 60 years of age who consumed 6 g of the dairy protein or a comparison, soy isoflavone protein, twice a day for eight weeks. DTaP vaccine administered at week 4. Non-parametric t-tests revealed a significant increase in Tetanus antibodies in the dairy group compared to the soy group at week 8. These findings suggest additional benefits of UV-C treated unheated dairy protein as a solution to counteract immunosenescence, but warrant further study in elderly and other populations that might benefit from immune system stimulation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting T-cell Aging to Remodel the Aging Immune System and Revitalize Geriatric Immunotherapy.
Chen M, Su Z, Xue J. · · 2025 · cited 6× · PMID 40153576 · DOI 10.14336/ad.2025.0061
Use of UV Treated Milk Powder to Increase Vaccine Efficacy in the Elderly.
Schaefer S, Hettinga KA, Cullor J, German JB, et al · · 2018 · cited 5× · PMID 30386327 · DOI 10.3389/fimmu.2018.02254

Verify or expand the search:

Other trials of Dairy protein

Trials testing the same drug.

NCT05813769 — Dairy and Plant Amino Acid Uptake. An Explorative Study · NA · completed

Other recruiting trials for Immunodeficiency

Currently open trials in the same condition.

NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
NCT06248957 — SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION · recruiting
NCT05907746 — Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Defici · Phase 2 · active not recruiting
NCT07406217 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients · Phase 2 · recruiting
NCT05587894 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Tri · Phase 2 · recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03557463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 11 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03557463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing